Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMC3 | ISIN: NL0015000YE1 | Ticker-Symbol: 0N6A
München
06.06.25 | 08:17
0,089 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TME PHARMA NV Chart 1 Jahr
5-Tage-Chart
TME PHARMA NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,0810,08709:16

Aktuelle News zur TME PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.TME Pharma N.V.: TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months379The Company is hereby clarifying and providing additional information on the financing announced on May 21, 2025 TME Pharma has secured private binding commitments from professional European...
► Artikel lesen
26.05.TME Pharma N.V.: TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders531Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
21.05.TME Pharma N.V.: TME Pharma Extends Its Financial Visibility by 12 Months404TME Pharma secures binding commitments for €1.7M proceeds from regular bonds repayable in cash during 12-month maturity period The transaction extends financial visibility into May 2026...
► Artikel lesen
05.05.TME Pharma N.V.: TME Pharma Announces That Nominated CEO Plans to Increase His Shareholding335Diede van den Ouden has disclosed plans for initial share purchases to become a more significant shareholder in TME Pharma prior to his nomination for appointment as CEO at the upcoming AGM in...
► Artikel lesen
05.05.Chef- und Strategiewechsel bei TME Pharma14
TME PHARMA Aktie jetzt für 0€ handeln
05.05.TME Pharma N.V.: TME Pharma Announces New Strategy1.161Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025 Operational costs to be...
► Artikel lesen
25.04.TME Pharma N.V.: TME Pharma Publishes 2024 Financial Results and Provides Operating Update392Total €7.6 million raised through multiple transactions All convertible debt instruments removed from balance sheet during 2024 Commitment to lean cost structure while focusing on...
► Artikel lesen
10.04.TME Pharma N.V.: TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities390Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
28.03.TME Pharma N.V.: TME Pharma Provides Results of Fifth Exercise of Warrants Z772556 Warrants Z were exercised resulting in the issuance of 695 new ordinary shares Outstanding 2,810,092 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to...
► Artikel lesen
13.03.TME Pharma N.V.: TME Pharma Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery479TME Pharma and Singapore Eye Research Institute (SERI) file new patent applications covering NOX-E36 for treatment of glaucoma filtration surgery and other ophthalmic diseases Preclinical...
► Artikel lesen
17.02.TME Pharma N.V.: TME Pharma CEO Message468Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor...
► Artikel lesen
29.01.TME Pharma N.V.: TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization647New Capabilities aim to strengthen corporate profile for strategic transactions and reinforce ongoing partnering discussions Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME)...
► Artikel lesen
20.01.TME Pharma N.V.: TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities456Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
23.12.24TME Pharma: Kapitalmaßnahme vollständig platziert696Mitte Dezember hat TME Pharma eine Kapitalerhöhung angekündigt. Jetzt kommt die Vollzugsmeldung. Alle angebotenen 52 Millionen Aktien sind platziert worden. Altaktionäre konnten für vier Aktien fünf...
► Artikel lesen
23.12.24TME Pharma N.V.: TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support33877.52% of the public offer was subscribed by existing shareholders using their pro rata subscription rights, totaling €2,015,549.10 and representing 40,310,982 new ordinary shares The remaining...
► Artikel lesen
20.12.24TME Pharma Provides Results of Fourth Exercise of Warrants Z529432 Warrants Z were exercised resulting in the issuance of 540 new ordinary shares Outstanding 2,810,648 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to...
► Artikel lesen
12.12.24TME Pharma: Garantierte Kapitalerhöhung für Liquiditätsdecke575Das Biotech-Unternehmen TME Pharma startet am 12. Dezember 2024 ein öffentliches Angebot über 2,6 Millionen Euro, das ausschließlich bestehenden Aktionären vorbehalten ist. Anteilseigner, die am Stichtag...
► Artikel lesen
12.12.24TME Pharma N.V.: TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025468Launch of a public offer on December 12, 2024, with a priority period from December 12 to December 18, 2024 only for shareholders of TME Pharma on record date of December 11, 20241, without preferential...
► Artikel lesen
04.12.24TME Pharma N.V.: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...847TME Pharma will focus its resources in the next seven months towards the newly prioritized strategic aims of completing a spin-out or a strategic transaction in addition to licensing or financing...
► Artikel lesen
23.11.24TME Pharma N.V.: TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting262Presentation highlights synergistic effect of combining NOX-A12's anti-CXCL12 activity with immune checkpoint inhibition in brain cancer models inducing a favorable tumor microenvironment (TME)...
► Artikel lesen
Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1